Pyxis Oncology price to book ratio PYXS

Market value divided by the book value of the company's net assets, since 2022.

Today, Oct 23, 2026: 12.2×
5-year median: 0.7×
Against its 5-year history: 95th; percentile: 0 is its lowest day, 100 its highest
5-year range: 0.2× to 28.4×
Peer median: 1.6×

Pyxis Oncology's price to book ratio is 12.2× as of Oct 23, 2026.

That is above its 5-year median of 0.7×, higher than on 95% of days in the last 5 years.

Over that time it ranged from 0.2× in Dec 2022 to 28.4× in Sep 2026.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.2×	1.0×	28.4×
2025	1.0×	0.4×	4.7×
2024	0.6×	0.6×	2.5×
2023	0.6×	0.3×	0.9×
2022	0.2×	0.2×	0.5×

Against its peers

Companies in Drug Manufacturers - General nearest Pyxis Oncology's size, closest first, today.

Company	Price to book ratio
PYXSPyxis Oncology	12.2×
NATRNatures Sunshine Products	1.3×
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
ATNMActinium Pharmaceuticals	1.6×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Pyxis Oncology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.